Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dinutuximab beta - Children's Cancer Research Institute/EUSA Pharma

Next Previous
Drug Profile

Dinutuximab beta - Children's Cancer Research Institute/EUSA Pharma

Alternative Names: APN 311; ch14.18/CHO; ISQETTE; QARZIBA; Qarziba

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Children's Cancer Research Institute
  • Developer Apeiron Biologics; BeiGene; Children's Cancer Research Institute; EUSA Pharma; Nagoya University; SIOPEN
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroblastoma

Most Recent Events

  • 28 Jun 2023 BeiGene completes a phase I trial in (In infants, In adolescents, In adults, In the elderly) in China (IV) (NCT05373901)
  • 02 Jun 2023 Updated efficacy data from the phase III SIOPEN trial in Neuroblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 07 Jun 2022 BeiGene initiates a phase I trial in (In infants, In adolescents, In adults, In the elderly) in China (IV) (NCT05373901)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top